📇 Rhumatologue · CAYENNE CEDEX · (973) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
5 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
59.7 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CENTRE HOSPITALIER DE CAYENNE
AV ALEXIS BLAISE BP 6006, 97306 CAYENNE CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Arthritis and rheumatism · 2012
Abstract Objective Th17 cells have been implicated in rheumatoid arthritis (RA). We hypothesized that the interaction of T cells with bone marrow–derived mesenchymal stem cells (BM‐MSCs) or with fibroblast‐ like synoviocytes (FLS) might, with the help of T cell–secreted inflammatory cytokines (i.e., interleukin‐17A [IL‐17A], tumor necrosis factor α [TNFα], and/or interferon‐γ [IFNγ]), promote Th17 cell expansion and activation. Methods Peripheral blood mononuclear cells (PBMCs) from healthy blood donors were cocultured with BM‐MSCs or FLS from RA patients or osteoarthritis (OA) patients. Cocultures were exposed to phytohemagglutinin with or without IL‐17A, TNFα, or IFNγ. Quantitative reverse transcription–polymerase chain reaction analysis, enzyme‐linked immunosorbent assay, and cytofluorometry were used to measure IL‐17A production. Results Interaction of PBMCs with BM‐MSCs inhibited Th1 and Th2 responses, but promoted Th17 cell expansion, as early as 24 hours, as demonstrated by increases in retinoic acid receptor–related orphan nuclear receptor γ or IL‐17A messenger RNA (mRNA) levels, IL‐17A secretion levels, and IL‐17A–secreting cell frequency, as well as by T cell switching to the Th17 pathway after 2 rounds of stimulation with MSCs. IL‐17A production was also increased in PBMCs stimulated with anti‐CD3 plus anti‐CD28 or in isolated CD3+ or CD45RO+ T cells, thus demonstrating the role of T cell activation. Levels of mRNA for IL‐6, IL‐8, and IL‐1β were further amplified when T cell–secreted inflammatory cytokines were added. Interestingly, OA FLS or RA FLS also enhanced IL‐17A and IL‐6 production, but only RA FLS enhanced IFNγ and IL‐1β production. We further demonstrated that MSC‐mediated Th17 promotion requires caspase 1 activation by using an inhibitory peptide and measuring its activity. Conclusion We found that the interaction of MSCs or FLS with T cells promotes the activation and expansion of Th17 cells through caspase 1 activation. Since proinflammatory and T cell–secreted inflammatory cytokines are also amplified, this mechanism may participate in the chronicity of RA.
Frontiers in medicine · 2021
Certain patients who recover from severe pneumonia due to coronavirus disease 2019 (COVID-19) remain symptomatic in the post-infectious period, either clinically, radiologically, or respiratory. The post-COVID-19 period is characterized by clinical symptoms of varying duration from one subject to another and does not seem to depend on the severity of initial pneumonia. The persisting inflammatory and/or immune reactions in the post-COVID-19 period may play a role in the development of pulmonary lesions. Here, we report the case of a 61-year-old man with severe COVID-19 pneumonia, complicated by acute respiratory distress syndrome and pulmonary embolism, which required the patient's admission to the intensive care unit and high-flow oxygen therapy. The patient was hospitalized for 23 days for the management of his severe COVID-19 pneumonia. Afterwards, he was discharged home following a negative SARS-CoV-2 PCR test. The post-COVID-19 period was characterized by a complex respiratory symptomatology associating cough, resting dyspnea, and exertional dyspnea requiring oxygen therapy for several weeks. Surprisingly, the follow-up chest CT scan performed 4 weeks after discharge revealed bilateral interstitial lung lesions. After ruling out pulmonary superinfection, the patient was treated with oral corticosteroid for 3 months at a digressive dose. In our case, the use of corticosteroid therapy in the post-COVID19 phase had improved the outcome of the lung disease. These benefits are characterized by a rapid symptomatic improvement, accelerated repair of pulmonary images, rapid oxygen withdrawal, and rapid return to daily activities.
Clinics and practice · 2021
Anti-MDA5 antibodies-associated amyopathic dermatomyositisis a rare autoimmune disease that involve polyarthritis, cutaneous and pulmonary manifestations. The development of rapidly progressing interstitial lung disease is a life-threatening complication. We report the case of a 45-year-old woman without medical history, who was addressed to the Pulmonary Department for a polyarthritis with dry cough and hypoxemic dyspnea. Initially there was neither cutaneous manifestation nor interstitial lung disease on chest CT scan. After a few days, the patient developed fatal acute respiratory failure with diffuse ground glass opacities. Identification of anti-MDA5 antibodies allowed establishing diagnosis, despite the fact that the first immunological assessment was negative. Corticosteroid bolus of 1 g for three days and immunosuppressive treatment by cyclophosphamide was only initiated at the acute respiratory distress syndrome stage. Given the rapidly unfavorable prognosis of this entity of amyopathic dermatomyositis, the testing for anti-MDA5 antibodies should be recommended in case of progressive pulmonary symptoms associated with joint signs in order to identify this disease at an early stage and to begin rapid and adequate management.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Frontiers in medicine · 2025 · Case Reports
Aissaoui H, Gaudard D, Hadj Amara G, Aboikoni A, et al.
Frontiers in medicine · 2021 · Case Reports
Aissaoui H, Eskenazi A, Suteau V, Adenis A, et al.
Clinics and practice · 2021 · Case Reports
Aissaoui H, Alsibai KD, Khayath N
Arthritis and rheumatism · 2012 · Journal Article
Eljaafari A, Tartelin ML, Aissaoui H, Chevrel G, et al.
Endoscopy international open · 2025 · Journal Article
Aboikoni A, Wallyn M, Bonifay T, Chhorn P, et al.